A Phase 3 interventional study of formoterol fumarate inhalation solution in Chronic Obstructive Pulmonary Disease, sponsored by Dey. Completed at 19 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2010-11-11.
Sponsored by Dey (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Pulmonary Disease, Chronic Obstructive by Viatris Inc. — none open to participants now, none under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Viatris Inc..
Among the 26 studies in Pulmonary Disease, Chronic Obstructive by Viatris Inc., this one is the 13th largest by enrollment, is one of 2 that started in 2007, is one of 12 in phase 3, and was the 9th registered.
5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →None of the 26 studies in Pulmonary Disease, Chronic Obstructive by Viatris Inc. is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →
Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 128 is above the median of 62 across 3,845 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 128 across the 26 interventional studies. Of the 26 that completed or were terminated, 11 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Dey, one of the names counted as Viatris Inc.. Under that name alone:
Dey is the lead sponsor of 21 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Pulmonary Disease, Chronic Obstructive by Viatris Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, Phase IIIb, randomized, double-blind, active-controlled, parallel-group, comparative study.
The objectives of this study are:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The primary efficacy endpoint will be the standardized area under the curve for FEV1 (FEV1 AUC0-3) over the 3-hour assessment period at End Study (Week 6/ET).
Time frame: 6 weeks
The record gives a start of Mar 2007, a primary completion of Oct 2007 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →